Literature DB >> 11082122

p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.

K K Meja1, P M Seldon, Y Nasuhara, K Ito, P J Barnes, M A Lindsay, M A Giembycz.   

Abstract

1. The extent to which the p38 mitogen-activated protein (MAP) kinase and MAP kinase kinase (MKK)-1-signalling pathways regulate the expression of granulocyte/macrophage colony-stimulating factor (GM-CSF) from LPS-stimulated human monocytes has been investigated and compared to the well studied cytokine tumour necrosis factor-alpha (TNF alpha). 2. Lipopolysaccharide (LPS) evoked a concentration-dependent generation of GM-CSF from human monocytes. Temporally, this effect was preceded by an increase in GM-CSF mRNA transcripts and abolished by actinomycin D and cycloheximide. 3. LPS-induced GM-CSF release and mRNA expression were associated with a rapid and time-dependent activation of p38 MAP kinase, ERK-1 and ERK-2. 4. The respective MKK-1 and p38 MAP kinase inhibitors, PD 098059 and SB 203580, maximally suppressed LPS-induced GM-CSF generation by >90%, indicating that both of these signalling cascades co-operate in the generation of this cytokine. 5. Electrophoretic mobility shift assays demonstrated that LPS increased nuclear factor kappa B (NF-kappa B) : DNA binding. SN50, an inhibitor of NF-kappa B translocation, abolished LPS-induced NF-kappaB : DNA binding and the elaboration of TNFalpha, a cytokine known to be regulated by NF-kappaB in monocytes. In contrast, SN50 failed to affect the release of GM-CSF from the same monocyte cultures. 6. Collectively, these results suggest that the generation of GM-CSF by LPS-stimulated human monocytes is regulated in a co-operative fashion by p38 MAP kinase- and MKK-1-dependent signalling pathways independently of the activation of NF-kappa B.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082122      PMCID: PMC1572440          DOI: 10.1038/sj.bjp.0703684

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  66 in total

1.  Expression of granulocyte/macrophage-colony-stimulating factor, interleukin-8 and RANTES in the bronchial epithelium of mild asthmatics is down-regulated by inhaled beclomethasone dipropionate.

Authors:  R J Davies; J H Wang; C J Trigg; J L Devalia
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

2.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.

Authors:  J C Lee; J T Laydon; P C McDonnell; T F Gallagher; S Kumar; D Green; D McNulty; M J Blumenthal; J R Heys; S W Landvatter; J E Strickler; M M McLaughlin; I R Siemens; S M Fisher; G P Livi; J R White; J L Adams; P R Young
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

3.  Constitutive nuclear NF-kappa B in cells of the monocyte lineage.

Authors:  M Frankenberger; A Pforte; T Sternsdorf; B Passlick; P A Baeuerle; H W Ziegler-Heitbrock
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

4.  Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes.

Authors:  H W Ziegler-Heitbrock; T Sternsdorf; J Liese; B Belohradsky; C Weber; A Wedel; R Schreck; P Bäuerle; M Ströbel
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

5.  Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma.

Authors:  K L Woolley; E Adelroth; M J Woolley; R Ellis; M Jordana; P M O'Byrne
Journal:  Am J Respir Crit Care Med       Date:  1995-06       Impact factor: 21.405

6.  Selective enhancement of GM-CSF, TNF-alpha, IL-1 beta and IL-8 production by monocytes and macrophages of asthmatic subjects.

Authors:  M P Hallsworth; C P Soh; S J Lane; J P Arm; T H Lee
Journal:  Eur Respir J       Date:  1994-06       Impact factor: 16.671

7.  Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms.

Authors:  P Wang; P Wu; M I Siegel; R W Egan; M M Billah
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

8.  Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

Authors:  M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

9.  Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence.

Authors:  Y Z Lin; S Y Yao; R A Veach; T R Torgerson; J Hawiger
Journal:  J Biol Chem       Date:  1995-06-16       Impact factor: 5.157

10.  CD14-dependent activation of protein kinase C and mitogen-activated protein kinases (p42 and p44) in human monocytes treated with bacterial lipopolysaccharide.

Authors:  M K Liu; P Herrera-Velit; R W Brownsey; N E Reiner
Journal:  J Immunol       Date:  1994-09-15       Impact factor: 5.422

View more
  22 in total

1.  Manganese modulation of MAPK pathways: effects on upstream mitogen activated protein kinase kinases and mitogen activated kinase phosphatase-1 in microglial cells.

Authors:  Patrick L Crittenden; Nikolay M Filipov
Journal:  J Appl Toxicol       Date:  2011-01       Impact factor: 3.446

Review 2.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 3.  Chronic obstructive pulmonary disease * 12: New treatments for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

4.  NF-κB activation is cell type-specific in the heart.

Authors:  Efraín E Rivera-Serrano; Barbara Sherry
Journal:  Virology       Date:  2016-12-30       Impact factor: 3.616

5.  Free-fatty acid receptor-4 (FFA4) modulates ROS generation and COX-2 expression via the C-terminal β-arrestin phosphosensor in Raw 264.7 macrophages.

Authors:  Ameneh Cheshmehkani; Ilya S Senatorov; Jyothi Dhuguru; Ola Ghoneim; Nader H Moniri
Journal:  Biochem Pharmacol       Date:  2017-09-21       Impact factor: 5.858

6.  Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.

Authors:  P M Seldon; M A Giembycz
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

7.  Stimulus-dependent glucocorticoid-resistance of GM-CSF production in human cultured airway smooth muscle.

Authors:  Thai Tran; Darren J Fernandes; Michael Schuliga; Trudi Harris; Linda Landells; Alastair G Stewart
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  Verotoxin activates mitogen-activated protein kinase in human peripheral blood monocytes: role in apoptosis and proinflammatory cytokine release.

Authors:  Pamela Cameron; Susan J Smith; Mark A Giembycz; Dino Rotondo; Robin Plevin
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

9.  Severely obese have greater LPS-stimulated TNF-alpha production than normal weight African-American women.

Authors:  Michael L Kueht; Brian K McFarlin; Rebecca E Lee
Journal:  Obesity (Silver Spring)       Date:  2008-12-04       Impact factor: 5.002

10.  Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.

Authors:  A Brosbøl-Ravnborg; C L Hvas; J Agnholt; J F Dahlerup; I Vind; A Till; P Rosenstiel; P Höllsberg
Journal:  Clin Exp Immunol       Date:  2008-12-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.